Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 110.00 105.00 115.00 110.00 110.00 110.00 2,162,628 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.1 -7.0 -13.3 - 56

Maxcyte Share Discussion Threads

Showing 101 to 124 of 125 messages
Chat Pages: 5  4  3  2  1
DateSubjectAuthorDiscuss
25/10/2019
06:50
Yep - patience could well be rewarded here
edwardt
24/10/2019
18:05
Progress on the CARMA trial - sounds good 'The dose escalation trial is evaluating the safety and tolerability, as well as preliminary efficacy, of MCY-M11 administered intraperitoneally across a series of ascending dose-level cohorts. In the first two cohorts, the infusion of MCY-M11 has been well tolerated in all patients treated. No dose-limiting toxicities, infusion-related adverse events, on-target or off-target toxicities, or other unwanted events were observed.' So they're around half-way through - 2 out of 4 cohorts - and a little past half-way on the timescale. Not too bad as these things go...
supernumerary
07/10/2019
18:44
No, just not looking in this direction. I was struck by this comment in the interims: "...the management team is evaluating independent sources of financing for CARMA along with the timing and level of clinical and pipeline investments beyond the current trial." Obviously looking at funding, but maybe also considering a CARMA spinoff? This is a commercially very astute management, so developments in this direction could be interesting.
supernumerary
07/10/2019
18:12
Pretty impressive rns - mr market sound asleep.
edwardt
25/7/2019
12:40
You could be right!
supernumerary
24/7/2019
15:13
very large volume gone through.... hope that marks a bottom!
edwardt
22/7/2019
16:56
The Capital Markets day presentation has turned up, here: https://www.maxcyte.com/investors/results-reports-presentations/corporate-presentations/ They've put it after the 2017/18 stuff, presumably because that's easier than rewriting the web page, but it looks a bit amateurish to me. It also seems to take an age to start as I don't think it will play the first video until it's downloaded all of them :¬( The presentations look excellent as far as I've got, although I'm having a lot of stuttering on replay, so I'll leave the rest for a while to see if it goes away. A link on CAR-Ts that may be of interest: https://www.fiercebiotech.com/research/a-personalized-car-t-to-attack-every-solid-tumor-pact-pharma-has-a-plan
supernumerary
20/7/2019
08:30
Folks, excuse the novice question but why is the sell so much below the buy (mine is 120p vs 128p on HL)? People seem to be dumping these shares left right and centre so doesn’t that drive the buy price down?
finster007
18/7/2019
10:27
New Trinity Delta note: https://www.trinitydelta.org/wp-content/uploads/2019/07/MaxCyte-Update-170719.pdf
timbo003
15/7/2019
21:16
If it doesn’t show soon, message me privately and I’ll photo and send it to you
gutterhead
15/7/2019
14:04
Whoops - just checked it, and it's from 2018. Still no sign on their website of either of the new ones...
supernumerary
12/7/2019
17:30
Yes. That’s it.
gutterhead
12/7/2019
16:11
OK, the proactive one is here: https://www.youtube.com/watch?v=Dv6t3ZjjXa4 Something to pass the weekend with, if tennis, cricket and F1 don't interest...
supernumerary
12/7/2019
12:57
Any further comments? Is it available anywhere? The Capital Markets presentation, which I guess would have been much the same, is expected to go on the website, but there's no sign of it yet.
supernumerary
12/7/2019
11:59
Great presentation at proactive investor evening last night.
gutterhead
10/7/2019
07:07
any views on when they will raise? looks a superb business but needs to sort out balance sheet. i am in for a few in advance of the institutional placement...
edwardt
07/7/2019
11:09
dave - I don't think so. He's removed the full list of holdings from his site - doesn't like his trading being tracked I guess! - so it's impossible to be sure, but the last figures I can find are for December 2017, when there was no trace of Maxcyte. It seems unlikely he's bought anything much since then - he had more than enough small biotech as it was. pug - to get EIS (substantial) tax benefits you have to hold for 3 years, so unlikely to be them. It is thinly-traded, though, so any buy/sell is going to move the price, but another day like Friday and the company will have to say something. A pity this is so unloved - there's huge interest in CAR-T. I see a nearly two-hour documentary on BBC2 tonight on a trial for CAR-T in leukemia: https://www.bbc.co.uk/programmes/m0006nzt Probably a lot more emotion than science, but probably still worth a watch.
supernumerary
06/7/2019
19:53
More likely those who bought at IPO and now locking in profits (that is if I undersatnd the EIS scheme correctly - as expalined by TIMBO in the heading) or possibly MOS tip buyers having stop-loss points being triggered. Woodford lot listed on coy web-site as a significant holder. Also a Delaware registered company which is a Red Flag for some .
pugugly
06/7/2019
11:13
Woodford selling, (not sure if he has a holding)?
davep4
05/7/2019
18:29
Mmmm... joint broker appointed in June - fund raising? Or just a holder getting out?
supernumerary
26/5/2019
10:06
Midas - Mail on Sunday BUY tip so should be good for a bounce on Tuesday - Still usual high risk mini-pharma (imo) https://www.dailymail.co.uk/money/investing/article-7069991/MIDAS-SHARE-TIPS-Medical-group-MaxCyte-finger-pulse.html
pugugly
08/5/2019
15:46
Hard to disagree with any of that, but the fact remains that over the last couple of years the share price has fallen steadily, and without dividends that and promises are all you've got. I think they might have to come a bit cleaner about the mid-term pipeline. I've got no idea whether their licensees are all in pre-clinical or whether some at least are closer to major milestones. Since that's a major part of the value proposition, in particular in potentially ending the need for continual cash raises, it needs more visibility to reassure investors. An indication of efficacy for MCY-M11 would also be useful!
supernumerary
08/5/2019
11:50
How to find a bargain in the British market By: Richard Penny 19/04/2019 Each week, a professional investor tells us where he’d put his money. This week: Richard Penny of the FP CRUX UK Special Situations Fund chooses three top-quality stocks. Investment is often characterised as a trade-off between value and growth. However, this is not the case. Growth is a feature of a business, and value is a reflection of what you pay for shares in relation to their inherent qualities. It is possible for a low-growth company to be expensive, while growing companies can also be acquired cheaply. Investors are always on the hunt for a “bargain”;: high-quality growth at an attractive valuation. When it comes to finding these, we consider key factors to be an ability to generate cash, management demonstrating alignment with shareholders’ interests by investing in the business, and the sustainability of growth and returns. Smaller businesses often display these characteristics, and because institutional investors tend to ignore them they can trade at big discounts to larger peers. Sometimes a business that would be highly valued as a standalone business is tucked away inside a large global entity. Bargains also arise when a company looking to grow depresses current profits by investing in new areas, prompting investors to mark it down, thus masking its true value. Analysing the reasons why a seemingly high-quality company has a downtrodden valuation is important. By tuning out market noise and taking a long-term view, you will greatly improve your odds of finding a bargain in the UK market. A leader in healthcare Among the smaller companies at the forefront of rapid developments in the healthcare sector is MaxCyte (Aim: MXCT), a world leader in the field of gene therapy. MaxCyte supplies machines critical to the modification of human genes to 20 of the world’s top 25 pharmaceutical companies and boasts a portfolio of around 70 licensing deals. The investment case includes MaxCyte’s commitment to undertaking clinical trials to combat ovarian cancer. This is a riskier part of the business, but it could pay dividends: other similar platforms are selling at multiples of MaxCyte’s current valuation.
davep4
08/5/2019
09:35
I'm struggling to understand what's happening here. I thought the results were good, this is a positive result, everything seems on track, but it remains unloved. Is it just worries about money, or is there a holder who's keen to reduce? Tim - was there any indication from the presentation of when they saw income from their '70 partnered programme licenses in cell therapy with more than 35 licensed for clinical use, including four announced commercial licenses covering potentially more than 30 products with aggregate potential milestones of more than $250m plus significant additional potential milestones from the multi-drug commercial agreement with Kite announced 1 March 2019.' arriving? This must hold the key to their finances going forward.
supernumerary
Chat Pages: 5  4  3  2  1
Your Recent History
LSE
MXCT
Maxcyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191115 21:03:32